An investigation for investors in GenMark Diagnostics, Inc (NASDAQ:GNMK) shares over potential securities laws violations by GenMark Diagnostics was announced.
San Diego, CA -- (SBWIRE) -- 12/08/2017 -- GenMark Diagnostics, Inc is under investigation over possible violations of securities laws in connection with certain financial statements. The investigation was announced for investors in NASDAQ:GNMK shares.
Investors who purchased shares of GenMark Diagnostics, Inc (NASDAQ:GNMK), have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of GenMark Diagnostics, Inc (NASDAQ:GNMK) concerning whether a series of statements by GenMark Diagnostics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Carlsbad, CA based GenMark Diagnostics, Inc. is a molecular diagnostics company that is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. GenMark Diagnostics, Inc reported that its annual Total Revenue rose from $39.41 million in 2015 to $49.27 million in 2016 and that its Net Loss increased from $42.20 million in 2015 to $50.60 million in 2016.
On November 2, 2017, GenMark Diagnostics, Inc President and CEO Hany Massarany stated during an earnings conference call that revenue recognition for expected placements of ePlex was slowed by a longer than expected customer evaluation and validation process prior to implementation of ePlex in routine clinical use.
Those who purchased shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego